Indicator name Reduction in antibiotic consumption per 1,000 admissions 80% of 0.25% (0.20%) Indicator weighting (% of CQUIN scheme available) Description of indicator There are three parts to this indicator. Total antibiotic consumption per 1,000 admissions Total consumption of carbapenem per 1,000 admissions Total consumption of piperacillin-tazobactam per 1,000 admissions Total antibiotic consumption as measured by Defined Daily Dose (DDD) Numerator Total consumption of carbapenem as measured by Defined Daily Dose (DDD) Total consumption of piperacillin-tazobactam as measured by Defined Daily Dose (DDD) admissions divided by 1,000 Denominator Rationale for inclusion Antimicrobial resistance (AMR) has risen alarmingly over the last 40 years and inappropriate and overuse of antimicrobials is a key driver. The number of new classes of antimicrobials coming to the market has reduced in recent years and between 2010 and 2013, total antibiotic prescribing in England increased by 6%. This leaves the prospect of reduced treatment options when antimicrobials are life-saving and standard surgical procedures could become riskier with widespread antimicrobial resistance. An AMR aims to reduce total antibiotic consumption measured as defined daily doses (DDDs) per 1000 admissions as well as to obtain evidence of antibiotic review within 72 hours of commencing an antibiotic. The CQUIN has two parts, the first aimed at reducing total antibiotic consumption and certain broad-spectrum antibiotics and the second focussed on antimicrobial stewardship and ensuring antibiotic review within 72 hours.
Indicator name Reduction in antibiotic consumption per 1,000 admissions Indicator weighting (% of CQUIN scheme available) 80% of 0.25% (0.20%) Description of indicator There are three parts to this indicator. Total antibiotic consumption per 1,000 admissions Total consumption of carbapenem per 1,000 admissions Total consumption of piperacillin-tazobactam per 1,000 admissions Numerator Total antibiotic consumption as measured by Defined Daily Dose (DDD) Total consumption of carbapenem as measured by Defined Daily Dose (DDD) Total consumption of piperacillin-tazobactam as measured by Defined Daily Dose (DDD) Denominator admissions divided by 1,000 Rationale for inclusion Antimicrobial resistance (AMR) has risen alarmingly over the last 40 years and inappropriate and overuse of antimicrobials is a key driver. The number of new classes of antimicrobials coming to the market has reduced in recent years and between 2010 and 2013, total antibiotic prescribing in England increased by 6%. This leaves the prospect of reduced treatment options when antimicrobials are life-saving and standard surgical procedures could become riskier with widespread antimicrobial resistance. An AMR aims to reduce total antibiotic consumption measured as defined daily doses (DDDs) per 1000 admissions as well as to obtain evidence of antibiotic review within 72 hours of commencing an antibiotic. The CQUIN has two parts, the first aimed at reducing total antibiotic consumption and certain broad-spectrum antibiotics and the second focussed on antimicrobial stewardship and ensuring antibiotic review within 72 hours.
cquin-nat-indictrs-v3.docx